CompletedEUCTR 2007-007555-14
An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major ...
This historical record does not confirm current site availability.
Historical research recordBulgaria + HungaryBipolarity
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Bulgaria · Hungary
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 240
- Sponsor
- Cephalon, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Bulgaria, Hungary
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2007-007555-14
- Official title
Show the full official title
An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major ...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBulgaria · Hungary
Questions about this study
Who is behind this study?
The study sponsor is Cephalon, Inc.
